These novel drug approvals — meaning new products never before approved or marketed in the U.S. — and drugs approved in new settings included treatments for diseases and conditions such as COVID-19; HIV; smallpox; influenza; neurological conditions; heart, blood, kidney and endocrine diseases; and different cancers.
Here are four other things to know from the FDA’s Center for Drug Evaluation and Research report:
1. 2022 saw the 40th FDA-approved biosimilar.
2. Fifty-four percent of the novel drug approvals were for rare diseases, including a rare cancer that begins in the eye.
3. Twenty-five of the 37 novel approvals, or 68 percent, were first approved in the U.S.
4. Fifty-four percent were first-in-class drugs, meaning they had “mechanisms of action different from those of existing therapies.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.